|
FY2018
12 months to Dec 31, 2018
|
FY2017
12 months to Dec 31, 2017
|
|
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Research and development-licenses acquired, expensed | ||
| Non-cash research and development expenses | ||
| Depreciation | ||
| Amortization of debt discount and debt issuance costs | ||
| Stock-based compensation | ||
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | ||
| Inventory | ||
| Prepaid expenses | ||
| Accounts payable | ||
| Accrued expenses | ||
| Accrued interest | ||
| Due to related party | ||
| Deferred revenue | ||
| Net cash used in operating activities | ||
| Cash flows from investing activities | ||
| Purchase of fixed assets | ||
| Purchase of research and development licenses | ||
| Net cash used in investing activities | ||
| Cash flows from financing activities | ||
| Payment of note payable | ||
| Debt issuance costs | ||
| Proceeds from the issuance of debt | ||
| Payment of offering cost in connection with issuance of Series A preferred stock | ||
| Proceeds from exercise of stock options | ||
| Proceeds from the issuance of common stock | ||
| Payment of offering cost in connection with issuance of common stock | ||
| Net cash provided by financing activities | ||
| Net increase in cash and equivalents | ||
| Cash and equivalents at the beginning of the year | ||
| Cash and equivalents at the end of the year | ||
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | ||
| Supplemental disclosure of noncash investing and financing activities: | ||
| Shares issued from the early exercise of options | ||
| Change in note payable |
Loading...
